Skip to main content

Table 1 Summary of clinical data in each group of patients with COVID related vasculopathy

From: Imaging of COVID-19 vasculopathy from head to toe: Egyptian collective experience after 2 years of the pandemic

+Clinical parameters Neuro-vasculopathy (262/282) Pulmonary vasculopathy (10/282) GIT vasculopathy (7/282) Peripheral limb vasculopathy (3/282)
[I] Age
  41–50 years 7 (3%)
  51–60 years 43 (16%) 4 (57%) 2 (67%)
  61–70 years 192 (73%) 9 (90%) 3 (43%) 1 (33%)
  71–80 years 14 (5%) 1 (10%)
  81–90 years 6 (2%)
[II] Sex
  Male 188 (72%) 10 (100%) 3 (43%) 3 (100%)
  Female 74 (28%) 4 (57%)
[III] Chest symptoms
  Present 247 (94%) 10 (100%) 6 (86%) 2 (67%)
  Absent (initial presentation by vasculopathy) 15 (6%) 1 (14%) 1 (33%)
[IV] Time of clinical presentation from onset of chest disease
  1st week 102 (39%)
  2nd week 111 (42%) 5 (50%) 3 (43%) 1 (33%)
  3rd week 23 (9%) 3 (30%) 3 (43%) 1 (33%)
  4th week 6 (2%) 2 (20%)
  2nd month 3 (1%) (vasculitis)
  3rd month 2 (1%) (vasculitis)
[V] Main complaint DLC 257 (98%) Fever 7 (70%) Abd. Pain 7 (100%) Leg pain: 3 (100%)
   Weakness/paresis 243 (93%) Cough 10 (100%) Vomiting 7 (100%)
   Headache 5 (2%) Dyspnea 10 (100%) Hematemesis 4 (57%)
   Dysarthria 4 (2%) Chest pain 10 (100%) Melena 4 (57%)
   Vertigo 3 (1%)    Constipation 3 (43%)
   Tinnitus 2 (1%)    Diarrhea 4 (57%)
   Blurred vision 2 (1%)     
[VI] Comorbidities
  Diabetes 24 (9%) 3 (30%) 2 (28%) 1 (33%)
  Hypertension 120 (46%) 3 (30%) 3 (43%) 2 (67%)
  Cardiomegaly (incidental) 78 (30%) 2 (20%) 4 (57%) 2 (67%)
  Hepatic disease 18 (7%)
  Renal disease 28 (11%)
  Neoplastic 9 (3%)